Investigators reported results from the first randomized controlled trial of office-based laser photocoagulation to standard TURBT for low-grade Ta bladder tumors.

UGN-102 showed high complete response rates in both ENVISION and ATLAS trials for low-grade, intermediate-risk NMIBC. Dysuria was the most common side effect of UGN-102, with other side effects ...

Approximately 1 in 10 patients with Ta low-grade NMIBC recur after 5 years, warranting continued surveillance. Nearly 10% of patients initially diagnosed with Ta low-grade nonmuscle-invasive bladder ...

UGN-102 achieved a 78% complete response rate at 3 months in the phase 3 ENVISION trial for recurrent low-grade NMIBC. The FDA's Oncologic Drugs Advisory Committee narrowly voted against the ...

Zusduri is expected to be available on or around July 1, 2025. The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade ...

(RTTNews) - UroGen Pharma Ltd. (URGN) said that the U.S. Food and Drug Administration accepted the New Drug Application or NDA for investigational drug UGN-102 (mitomycin) for intravesical solution.

Findings published in the journal of Clinical Genitourinary Cancer show patients remained event-free for a median of two years after achieving complete response with ZUSDURI (mitomycin) intravesical ...

A phase II prospective, open-label, multi-center, single-arm study of sasanlimab plus sacituzumab govitecan in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) pts: SSANTROP (APRO07-2022).

Determining an immunohistochemical profile to predict response to intravesical bacillus Calmette–Guérin (BCG) in patients with high-grade non-muscle invasive bladder cancer. This is an ASCO Meeting ...

President and CEO Liz Barrett outlined the company’s urothelial cancer focus and provided an update on the commercial launch of its recently approved bladder cancer therapy during a fireside chat. RTG ...

Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay ...